Salutary roles of CD39 in transplantation

Transplantation Reviews

Volumn 21, Issue 1, 2007, Pages 54-63

  Dwyer, Karen M ^a,b   Deaglio, Silvia ^c   Crikis, Sandra ^a,b   Gao, Wenda ^d   Enjyoji, Keiichi ^d   Strom, Terry B ^d   Cowan, Peter J ^a,b   d'Apice, Anthony J F ^a,b   Robson, Simon C ^d  

^a Immunology Research Centre   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF TURIN   (Italy)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; CD103 ANTIGEN; CD39 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR8; CLOPIDOGREL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEXTRAN SULFATE; HEPARIN; HYDROLASE; INTERLEUKIN 2 RECEPTOR ALPHA; L SELECTIN; NUCLEOTIDE; NUCLEOTIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE; PURINE P2 RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; ENDOTHELIUM; ENZYME REGULATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; HYDROLYSIS; HYPERACUTE GRAFT REJECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; NONHUMAN; ORGAN TRANSPLANTATION; PATHOPHYSIOLOGY; PHENOTYPIC VARIATION; POSTOPERATIVE THROMBOSIS; PREDICTION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THROMBOSIS; XENOTRANSPLANTATION;

EID: 34147209885     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2007.01.005     Document Type: Article

References (105)

1. Platt J.L., Lin S.S., and McGregor C.G. Acute vascular rejection. Xenotransplantation 5 (1998) 169-175
2. Platt J.L. New directions for organ transplantation. Nature 392 (1998) 11-17
3. Robson S.C., Candinas D., Hancock W.W., et al. Role of endothelial cells in transplantation. Int Arch Allergy Immunol 106 (1995) 305-322
4. Seal J.B., and Gewertz B.L. Vascular dysfunction in ischemia-reperfusion injury. Ann Vasc Surg 19 (2005) 572-584
5. Bach F.H., Winkler H., Ferran C., et al. Delayed xenograft rejection. Immunol Today 17 (1996) 379-384
6. Robson S.C., Cooper D.K., and d'Apice A.J. Disordered regulation of coagulation and platelet activation in xenotransplantation. Xenotransplantation 7 (2000) 166-176
7. Kobie J.J., Shah P.R., Yang L., et al. T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5′-adenosine monophosphate to adenosine. J Immunol 177 (2006) 6780-6786
8. Hasko G., and Cronstein B.N. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 25 (2004) 33-39
9. Sitkovsky M.V., and Ohta A. The 'danger' sensors that STOP the immune response: the A2 adenosine receptors?. Trends Immunol 26 (2005) 299-304
10. Abbracchio M.P., and Burnstock G. Purinoceptors: are there families of P2X and P2Y purinoceptors?. Pharmacol Ther 64 (1994) 445-475
11. Harden T.K., Lazarowski E.R., and Boucher R.C. Release, metabolism and interconversion of adenine and uridine nucleotides: implications for G protein-coupled P2 receptor agonist selectivity. Trends Pharmacol Sci 18 (1997) 43-46
12. Kaczmarek E., Koziak K., Sevigny J., et al. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 271 (1996) 33116-33122
13. Marcus A.J., Broekman M.J., Drosopoulos J.H., et al. The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39. J Clin Invest 99 (1997) 1351-1360
14. Zimmermann H. 5′-Nucleotidase: molecular structure and functional aspects. Biochem J 285 Pt 2 (1992) 345-365
15. Maliszewski C.R., Delespesse G.J., Schoenborn M.A., et al. The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization. J Immunol 153 (1994) 3574-3583
16. Wang T.F., and Guidotti G. CD39 is an ecto-(Ca2+, Mg2+)-apyrase. J Biol Chem 271 (1996) 9898-9901
17. Schulte Am E.J., Sevigny J., Kaczmarek E., et al. Structural elements and limited proteolysis of CD39 influence ATP diphosphohydrolase activity. Biochemistry 38 (1999) 2248-2258
18. Grinthal A., and Guidotti G. Dynamic motions of CD39 transmembrane domains regulate and are regulated by the enzymatic active site. Biochemistry 43 (2004) 13849-13858
19. Heine P., Braun N., Sevigny J., et al. The C-terminal cysteine-rich region dictates specific catalytic properties in chimeras of the ectonucleotidases NTPDase1 and NTPDase2. Eur J Biochem 268 (2001) 364-373
20. Enjyoji K., Sevigny J., Lin Y., et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 5 (1999) 1010-1017
21. Sevigny J., Levesque F.P., Grondin G., et al. Purification of the blood vessel ATP diphosphohydrolase, identification and localisation by immunological techniques. Biochim Biophys Acta 1334 (1997) 73-88
22. Sawdey M., Podor T.J., and Loskutoff D.J. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J Biol Chem 264 (1989) 10396-10401
23. Stern D., Nawroth P., Handley D., et al. An endothelial cell-dependent pathway of coagulation. Proc Natl Acad Sci U S A 82 (1985) 2523-2527
24. Bevilacqua M.P., Pober J.S., Majeau G.R., et al. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 160 (1984) 618-623
25. Nawroth P.P., Handley D.A., Esmon C.T., et al. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci U S A 83 (1986) 3460-3464
26. Pober J.S. Warner-Lambert/Parke-Davis award lecture. Cytokine-mediated activation of vascular endothelium. Physiology and pathology. Am J Pathol 133 (1988) 426-433
27. Baeuerle P.A., and Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12 (1994) 141-179
28. Siebenlist U., Franzoso G., and Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 10 (1994) 405-455
29. Zwacka R.M., Zhang Y., Halldorson J., et al. CD4(+) T-lymphocytes mediate ischemia/reperfusion-induced inflammatory responses in mouse liver. J Clin Invest 100 (1997) 279-289
30. Hernandez L.A., Grisham M.B., Twohig B., et al. Role of neutrophils in ischemia-reperfusion-induced microvascular injury. Am J Physiol 253 (1987) H699-H703
31. Palmer R.M., Ferrige A.G., and Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327 (1987) 524-526
32. Hein T.W., Zhang C., Wang W., et al. Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase. FASEB J 17 (2003) 2328-2330
33. DeFily D.V. Control of microvascular resistance in physiological conditions and reperfusion. J Mol Cell Cardiol 30 (1998) 2547-2554
34. Erlich J.H., Boyle E.M., Labriola J., et al. Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation. Am J Pathol 157 (2000) 1849-1862
35. Golino P., Ragni M., Cirillo P., et al. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nat Med 2 (1996) 35-40
36. Koo D.D., Welsh K.I., Roake J.A., et al. Ischemia/reperfusion injury in human kidney transplantation: an immunohistochemical analysis of changes after reperfusion. Am J Pathol 153 (1998) 557-566
37. Dunzendorfer S., Reinisch C.M., Kaneider N.C., et al. Inhibition of plasma-dependent monocyte chemokinesis and cytokine-triggered endothelial activation for neutrophil transmigration by administration of clopidogrel in man. Acta Med Austriaca 29 (2002) 100-106
38. Kanko M., Maral H., Akbas M.H., et al. Protective effects of clopidogrel on oxidant damage in a rat model of acute ischemia. Tohoku J Exp Med 205 (2005) 133-139
39. Banz Y., Hess O.M., Robson S.C., et al. Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischaemia/reperfusion injury. Eur Heart J 26 (2005) 2334-2343
40. Kouretas P.C., Kim Y.D., Cahill P.A., et al. Nonanticoagulant heparin prevents coronary endothelial dysfunction after brief ischemia-reperfusion injury in the dog. Circulation 99 (1999) 1062-1068
41. Murry C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986) 1124-1136
42. Bolli R. The late phase of preconditioning. Circ Res 87 (2000) 972-983
43. Day Y.J., Li Y., Rieger J.M., et al. A2A adenosine receptors on bone marrow-derived cells protect liver from ischemia-reperfusion injury. J Immunol 174 (2005) 5040-5046
44. Day Y.J., Huang L., McDuffie M.J., et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 112 (2003) 883-891
45. Day Y.J., Huang L., Ye H., et al. Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-{gamma}. J Immunol 176 (2006) 3108-3114
46. Yang Z., Day Y.J., Toufektsian M.C., et al. Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 111 (2005) 2190-2197
47. Lee H.T., and Lineaweaver W.C. Protection against ischemic-reperfusion injury of skeletal muscle: role of ischemic preconditioning and adenosine pretreatment. J Reconstr Microsurg 12 (1996) 383-388
48. Ross S.D., Tribble C.G., Linden J., et al. Selective adenosine-A2A activation reduces lung reperfusion injury following transplantation. J Heart Lung Transplant 18 (1999) 994-1002
49. Peralta C., Bartrons R., Riera L., et al. Hepatic preconditioning preserves energy metabolism during sustained ischemia. Am J Physiol Gastrointest Liver Physiol 279 (2000) G163-G171
50. Kim J.S., Qian T., and Lemasters J.J. Mitochondrial permeability transition in the switch from necrotic to apoptotic cell death in ischemic rat hepatocytes. Gastroenterology 124 (2003) 494-503
51. Burne-Taney M.J., Yokota-Ikeda N., and Rabb H. Effects of combined T- and B-cell deficiency on murine ischemia reperfusion injury. Am J Transplant 5 (2005) 1186-1193
52. Ysebaert D.K., De Greef K.E., De B.A., et al. T cells as mediators in renal ischemia/reperfusion injury. Kidney Int 66 (2004) 491-496
53. De Greef K.E., Ysebaert D.K., Dauwe S., et al. Anti-B7-1 blocks mononuclear cell adherence in vasa recta after ischemia. Kidney Int 60 (2001) 1415-1427
54. Zhang M., Alicot E.M., Chiu I., et al. Identification of the target self-antigens in reperfusion injury. J Exp Med 203 (2006) 141-152
55. Lappas C.M., Day Y.J., Marshall M.A., et al. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med (2006) 2639-2648
56. Yokota N., Burne-Taney M., Racusen L., et al. Contrasting roles for STAT4 and STAT6 signal transduction pathways in murine renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 285 (2003) F319-F325
57. Burne M.J., Daniels F., El G.A., et al. Identification of the CD4(+) T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 108 (2001) 1283-1290
58. Deng J., Kohda Y., Chiao H., et al. Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury. Kidney Int 60 (2001) 2118-2128
59. Cowan P.J., Aminian A., Barlow H., et al. Renal xenografts from triple-transgenic pigs are not hyperacutely rejected but cause coagulopathy in non-immunosuppressed baboons. Transplantation 69 (2000) 2504-2515
60. Brenner P., Hinz M., Huber H., et al. The influence of antibody and complement removal with a Ig-Therasorb column in a xenogeneic working heart model. Eur J Cardiothorac Surg 15 (1999) 672-679
61. Kozlowski T., Ierino F.L., Lambrigts D., et al. Depletion of anti-Gal(alpha)1-3Gal antibody in baboons by specific alpha-Gal immunoaffinity columns. Xenotransplantation 5 (1998) 122-131
62. Simon P.M., Neethling F.A., Taniguchi S., et al. Intravenous infusion of Galalpha1-3Gal oligosaccharides in baboons delays hyperacute rejection of porcine heart xenografts. Transplantation 65 (1998) 346-353
63. Taniguchi S., Neethling F.A., Korchagina E.Y., et al. In vivo immunoadsorption of antipig antibodies in baboons using a specific Gal(alpha)1-3Gal column. Transplantation 62 (1996) 1379-1384
64. Zhong R., Luo Y., Yang H., et al. Improvement in human decay accelerating factor transgenic porcine kidney xenograft rejection with intravenous administration of gas914, a polymeric form of alphaGAL. Transplantation 75 (2003) 10-19
65. Kuwaki K., Tseng Y.L., Dor F.J., et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat Med 11 (2005) 29-31
66. Yamada K., Yazawa K., Shimizu A., et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue. Nat Med 11 (2005) 32-34
67. Byrne G.W., Schirmer J.M., Fass D.N., et al. Warfarin or low-molecular-weight heparin therapy does not prolong pig-to-primate cardiac xenograft function. Am J Transplant 5 (2005) 1011-1020
68. Houser S.L., Kuwaki K., Knosalla C., et al. Thrombotic microangiopathy and graft arteriopathy in pig hearts following transplantation into baboons. Xenotransplantation 11 (2004) 416-425
69. Shimizu A., Yamada K., Yamamoto S., et al. Thrombotic microangiopathic glomerulopathy in human decay accelerating factor-transgenic swine-to-baboon kidney xenografts. J Am Soc Nephrol 16 (2005) 2732-2745
70. Schulte E., Am J., Rogiers X., and Robson S.C. Molecular incompatibilities in hemostasis between swine and men-impact on xenografting. Ann Transplant 6 (2001) 12-16
71. Ierino F.L., Kozlowski T., Siegel J.B., et al. Disseminated intravascular coagulation in association with the delayed rejection of pig-to-baboon renal xenografts. Transplantation 66 (1998) 1439-1450
72. Cowan P.J., Aminian A., Barlow H., et al. Protective effects of recombinant human antithrombin III in pig-to-primate renal xenotransplantation. Am J Transplant 2 (2002) 520-525
73. Chen D., Weber M., McVey J.H., et al. Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant 4 (2004) 1958-1963
74. Pinsky D.J., Broekman M.J., Peschon J.J., et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest 109 (2002) 1031-1040
75. Ledent C., Vaugeois J.M., Schiffmann S.N., et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388 (1997) 674-678
76. Esmon C.T., Taylor Jr. F.B., and Snow T.R. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost 66 (1991) 160-165
77. Esmon C.T. Inflammation and thrombosis. J Thromb Haemost 1 (2003) 1343-1348
78. Mizumoto N., Kumamoto T., Robson S.C., et al. CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat Med 8 (2002) 358-365
79. Eltzschig H.K., Thompson L.F., Karhausen J., et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 104 (2004) 3986-3992
80. Synnestvedt K., Furuta G.T., Comerford K.M., et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 110 (2002) 993-1002
81. Sakaguchi S., Sakaguchi N., Asano M., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155 (1995) 1151-1164
82. Zheng X.X., Sanchez-Fueyo A., Domenig C., et al. The balance of deletion and regulation in allograft tolerance. Immunol Rev 196 (2003) 75-84
83. Zheng X.X., Sanchez-Fueyo A., Sho M., et al. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 19 (2003) 503-514
84. Fontenot J.D., Rasmussen J.P., Williams L.M., et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22 (2005) 329-341
85. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057-1061
86. von B.H. Mechanisms of suppression by suppressor T cells. Nat Immunol 6 (2005) 338-344
87. Mellor A.L., and Munn D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4 (2004) 762-774
88. Paust S., Lu L., McCarty N., et al. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci U S A 101 (2004) 10398-10403
89. Iellem A., Mariani M., Lang R., et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 194 (2001) 847-853
90. Salomon B., Lenschow D.J., Rhee L., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12 (2000) 431-440
91. Lehmann J., Huehn J., de la R.M., et al. Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. Proc Natl Acad Sci U S A 99 (2002) 13031-13036
92. Asseman C., Mauze S., Leach M.W., et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190 (1999) 995-1004
93. Chen M.L., Pittet M.J., Gorelik L., et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A 102 (2005) 419-424
94. Zhang N., Yang D., Dong H., et al. Adenosine A2a receptors induce heterologous desensitization of chemokine receptors. Blood 108 (2006) 38-44
95. Candinas D., Koyamada N., Miyatake T., et al. Loss of rat glomerular ATP diphosphohydrolase activity during reperfusion injury is associated with oxidative stress reactions. Thromb Haemost 76 (1996) 807-812
96. Imai M., Takigami K., Guckelberger O., et al. CD39/vascular ATP diphosphohydrolase modulates xenograft survival. Transplant Proc 32 (2000) 969
97. Robson S.C., Daoud S., Begin M., et al. Modulation of vascular ATP diphosphohydrolase by fatty acids. Blood Coagul Fibrinolysis 8 (1997) 21-27
98. Robson S.C., Kaczmarek E., Siegel J.B., et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med 185 (1997) 153-163
99. Guckelberger O., Sun X.F., Sevigny J., et al. Beneficial effects of CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 in murine intestinal ischemia-reperfusion injury. Thromb Haemost 91 (2004) 576-586
100. Dwyer K.M., Robson S.C., Nandurkar H.H., et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 113 (2004) 1440-1446
101. Crikis S., Dwyer K., Murray-Segal L., et al. Transgenic CD39 expression protects against renal ischaemia reperfusion injury. Xenotransplantation 12 (2005) 382
102. Li Y., Csizmadia E., Sevigny J., Enjyoji K., and Robson S. CD39/Nucleoside triphosphate diphosphohydrolase-1 (NTPDase-1) modulates allograft rejection and cellular immune responses. Am J Transplant (2003) 545
103. Imai M., Takigami K., Guckelberger O., et al. Modulation of nucleoside [correction of nucleotide] triphosphate diphosphohydrolase-1 (NTPDase-1)cd39 in xenograft rejection. Mol Med 5 (1999) 743-752
104. Koyamada N., Miyatake T., Candinas D., et al. Apyrase administration prolongs discordant xenograft survival. Transplantation 62 (1996) 1739-1743
105. Deaglio S., Dwyer K., Gao W., Friedman D., Usheva A., Erat A., et al. Generation of adenosine by regulatory T cells catalyzes immune suppression. J Exp Med (2007) [in press]